- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis, Lymph Node Mapping, Lymphadenectomy, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 7
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 436
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- PNB of SLN
- Procedure
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Melanoma, Lymph Node Cancer
- Interventions
- CMP-001, Nivolumab
- Drug · Biological
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cancer
- Interventions
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Lymphedema, Breast Cancer, Lymphedema
- Interventions
- axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA), Axillary lymphadenetomy alone, axillary lymphadenectomy with soft tissue reinforcement
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
- Interventions
- Delayed SLND, Late SLND
- Diagnostic Test
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- SLN mapping using technetium-99m +/- isosulfan blue dye, SLN mapping with ICG fluorescence using the Asimov Platform
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cancer of the Breast
- Interventions
- Axillary Reverse Mapping
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Endometrial Cancer
- Interventions
- Selective surgical staging, REFLEX
- Procedure
- Lead sponsor
- Rachel Miller
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Endometrial Cancer
- Interventions
- Lymphoseek plus Vital Blue Dye
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
- Interventions
- Binimetinib, Conventional Surgery, Encorafenib, Fluorothymidine F-18
- Drug · Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more
- Conditions
- Breast Neoplasms
- Interventions
- Fine needle aspiration biopsy (FNAB), Sentinel Lymph Node Biopsy
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Fludeoxyglucose F-18, Biospecimen Collection
- Drug · Other · Radiation + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 111
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 83 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 95
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
- Conditions
- Lung Cancer
- Interventions
- EBUS-TBNA
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Interventions
- CNTO 328
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Lymphedema
- Interventions
- Tourniquet Use
- Procedure
- Lead sponsor
- OrthoCarolina Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Charlotte, North Carolina
- Conditions
- Neck Dissection, Radical Lymph Node Dissection
- Interventions
- Indocyanine Green Solution, Lymphangiography
- Other · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • New York, New York • Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- RNA marker analysis of lymph node and primary tumors, microarray profiling of primary tumors, reverse transcriptase-polymerase chain reaction of lymph node specimens, diagnostic laboratory RNA and DNA biomarker analysis of primary tumors, regional lymph node dissection, lymph node staining for H&E and pancytokeratin IHC
- Genetic · Other · Procedure
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia
- Conditions
- Breast Cancer, Melanoma
- Interventions
- Methylene blue dye injection of sentinel lymph node
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota